Skip to main content

Year: 2023

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

Best Response to TCR-TBest Response to TCR-TTCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients hunTR® discovered new HLA class I and class II restricted TCRs that recognize driver mutations, including KRAS and TP53 Company continues to explore potential strategic alternatives; cost-savings measures expected to extend cash runaway into the second quarter of 2024HOUSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) — Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced financial results for the third quarter ended September 30, 2023. As previously announced, the Company is exploring strategic alternatives with Cantor Fitzgerald & Co. as its strategic...

Continue reading

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

JERUSALEM, Nov. 14, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and small therapeutic proteins, today reported corporate updates and financial results for the third quarter ended September 30th, 2023. “Today, after over a year of steadfast transformation and execution, Entera stands as a premier oral peptide company.  It is our goal to potentially move five high value, first-in-class programs, Phase 1 through Phase 3, into the clinic by the end of 2025.” “Our disruptive and proprietary technology simultaneously inhibits gastrointestinal enzymatic degradation and consistently produces bioavailability of peptides, via a simple tablet format (around 6mm in diameter). Each of our oral peptide programs has been carefully selected based...

Continue reading

Global Bentonite Market Size to Reach USD 3.88 Billion in 2032 | Emergen Research

Increasing need for bentonite in the oil and gas industry, growing need for iron ore pellet production in steel manufacturing are major factors driving the Bentonite market revenue growth. Vancouver, Nov. 14, 2023 (GLOBE NEWSWIRE) — The global bentonite market has demonstrated a remarkable growth trajectory, reaching a size of USD 2.00 Billion in 2022, with expectations of a steady revenue Compound Annual Growth Rate (CAGR) of 6.5% during the forecast period. The market is propelled by several key factors, including the increasing demand for bentonite in the oil and gas industry, the rising need for iron ore pellet production in steel manufacturing, and growing demands from the drilling industry. Oil and Gas Industry Boosts Bentonite Market:  A major driver of the market is the escalating requirement for bentonite in the oil and...

Continue reading

Global Steam Flow Meters Market Size to Reach USD 997.75 Million in 2032 | Emergen Research

Rising demand for flow meters in the chemical industry, water and wastewater treatment industry are major factors driving the Steam Flow Meters market revenue growth. Vancouver, Nov. 14, 2023 (GLOBE NEWSWIRE) — The global steam flow meters market exhibited a robust growth trajectory in 2022, with a market size reaching USD 517.78 Million. The market is poised to continue its expansion, projecting a steady revenue CAGR of 6.7% during the forecast period. Market Drivers: The rising demand for flow meters in key industries such as chemicals, water and wastewater treatment, coupled with the imperative need for energy efficiency in power generation, remains a pivotal factor driving the market’s revenue growth. Steam flow meters play a crucial role in measuring steam flow rates across various industrial and commercial applications....

Continue reading

Global Injection Molding Machine Market Size to Reach USD 25.23 Billion in 2032 | Emergen Research

An injection molding machine is a fundamental manufacturing device, enabling the production of a diverse range of plastic products with precision and consistency. Vancouver, Nov. 14, 2023 (GLOBE NEWSWIRE) — The global injection molding machine market witnessed a notable market size of USD 17.50 billion in 2022, and it is set to maintain a steady growth trajectory with a projected revenue CAGR of 3.7% during the forecast period. Several key factors are driving this growth, including increased demand from the packaging industry and the automotive sector, a growing emphasis on energy efficiency, and consumer trends favoring on-the-go packaged products. Injection molding machines play a pivotal role in the production of plastic containers, caps, closures, and various packaging components, offering design flexibility and cost-effectiveness....

Continue reading

Global Smartphone Screen Protector Market Size to Reach USD 96.70 Billion in 2032 | Emergen Research

Rising global demand for premium smartphones and government initiatives for domestic manufacturing of smartphones and other components are major factors driving Smartphone Screen Protector market revenue growth. Vancouver, Nov. 14, 2023 (GLOBE NEWSWIRE) — The global smartphone screen protector market continues to expand, with a market size of USD 50.32 billion in 2022 and a projected rapid revenue compound annual growth rate (CAGR) of 6.8% during the forecast period. Several key factors are contributing to this growth, including rising global demand for premium smartphones, government initiatives for domestic manufacturing, and increased awareness about protecting smartphone screens. In today’s digital age, smartphones are essential for accessing online services, and governments in developing countries are promoting digitalization...

Continue reading

Global Lead Acid Battery Market Size to Reach USD 71.73 Billion in 2032 | Emergen Research

Rising demand for Uninterrupted Power System (UPS) systems, particularly in data centers and other critical infrastructure is another key factor driving revenue growth of the market Vancouver, Nov. 14, 2023 (GLOBE NEWSWIRE) — The global lead acid battery market, valued at USD 47.08 billion in 2022, is set to sustain a strong growth trajectory with a projected revenue compound annual growth rate (CAGR) of 4.3% during the forecast period. Key factors propelling this expansion include the rising demand for lead acid batteries, technological advancements, and a thriving telecom sector. Lead acid batteries, known for their reliability and cost-effectiveness, find extensive use in applications such as telecommunications, data centers, healthcare facilities, and emergency lighting systems. Notably, these batteries enjoy a remarkable recycling...

Continue reading

SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates

Raises combined $67.1M in private placement plus Tranche warrant exercise with syndicate of leading investors Received approval by the Human Research Ethics Committee (HREC) to commence a First-in-Human Phase 1 clinical trial investigating SAB-142 in Australia Appoints Michael G. King Jr. as new Chief Financial Officer SIOUX FALLS, S.D., Nov. 14, 2023 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today reported financial results for the third quarter ended October 31, 2023, and provided a company update. “The third quarter of 2023 was a pivotal growth point for SAB as we advance SAB-142, our T1D immunotherapy....

Continue reading

Beam Global Announces Third Quarter 2023 Results

Conference Call Tuesday November 14, 2023 at 8:30 A.M. ETBeam Global CEO Desmond Wheatley gives first public look at Beam Europe in this live in-depth virtual tour.SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) — Beam Global, (Nasdaq: BEEM, BEEMW), (the “Company”), the leading provider of innovative and sustainable infrastructure solutions for the electrification of transportation and energy security, today announced its Third Quarter results for the period ended September 30, 2023. Q3 2023 Financial HighlightsQuarterly revenue of $16.5 million, a 149% increase over Q3 2022 Record year-to-date revenues of $47.3 million, a 236% increase over 2022 Record Q3 EV ARC™ system deployments; increased 295% YOY Record year-to-date gross profit of $0.8 million, or 2% of revenues; year-to-date gross profit excluding...

Continue reading

atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and data from the EMP-01 (MDMA derivative) Phase 1 study is anticipated to report out later this year.   Phase 1 data of VLS-01 (a proprietary oral transmucosal film formulation of DMT) demonstrated that 160mg of VLS-01 reached exposure levels comparable to 30mg of IV DMT. Acceptance of three non-clinical poster presentations at upcoming medical meetings, including non-clinical data for RL-007 and two novel 5-HT2A receptor agonists, EGX-A and EGX-B. The Company’s $209M cash position and committed term loan funding is expected to fund operations into 1H 2026.NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.